2021
1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)?
Nguyen D, Bethel C, Taracilla M, Li Q, Dousa K, Kurz S, Nguyen L, Kreiswirth B, Boom W, Bonomo R. 1390. Durlobactam, a Diazabicyclooctane (DBO) β-lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of Mycobacterium tuberculosis (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)? Open Forum Infectious Diseases 2021, 8: 780-780. PMCID: PMC8643912, DOI: 10.1093/ofid/ofab466.1582.Peer-Reviewed Original ResearchB-lactamMultidrug-resistant TBTreatment of TBNovel therapiesMtb H37RvAvibactamRelebactamCarbapenemsClavulanateMicrodilution methodAcyl-enzyme complexTherapeutic potentialDurlobactamMeropenemMICDual actionTranspeptidasePre-incubationDiazabicyclooctaneMtbAmoxicillinPeriod of pre-incubationTuberculosis
2020
Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors
Dousa K, Kurz S, Taracila M, Bonfield T, Bethel C, Barnes M, Selvaraju S, Abdelhamed A, Kreiswirth B, Boom W, Kasperbauer S, Daley C, Bonomo R. Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Antimicrobial Agents And Chemotherapy 2020, 64: 10.1128/aac.00098-20. PMID: 32393499, PMCID: PMC7526840, DOI: 10.1128/aac.00098-20.Peer-Reviewed Original ResearchConceptsCeftaroline fosamilB-lactamB-lactamaseNontuberculous mycobacteriaB-lactamase inhibitorsD-carboxypeptidaseB-lactam antibioticsCell wall synthesis proteinsCeftarolineImipenemDiazabicyclooctane inhibitorSteady-state kinetic assaysAvibactamHighest acylation ratesMechanism-based approachGt;100-foldRelebactamSynthesis proteinsD-transpeptidasesKinetic assaysAcylation rateInhibitors
2019
1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy
Dousa K, Kurz S, Bethel C, Barnes M, Taracilla M, Selvaraju S, Jacobs M, Kreiswirth B, Kasperbauer S, Daley C, Bonomo R. 1385. Mechanism-Based, In Vitro Inhibition of Mycobacterium abscessus: Assessing β-Lactam Therapy. Open Forum Infectious Diseases 2019, 6: s503-s503. PMCID: PMC6809419, DOI: 10.1093/ofid/ofz360.1249.Peer-Reviewed Original ResearchB-lactamaseColony-forming unitsIn vitro susceptibility testingB-lactamase inhibitorsTherapeutically achievable concentrationsMab infectionRescue regimenMiddlebrook 7H9 brothVisible bacterial growthSusceptibility testingClinical isolatesImipenemBlaMabTreated patientsRelebactamAvibactamNontuberculous mycobacteriaB-lactamM. abscessusMAB isolatesTest agentsIn vitro inhibitionMAb complexesMAbMIC
2018
786. Ceftaroline and Avibactam? Is This a Potential Combination for Mycobacterium abscessus Infection?
Dousa K, Kreiswirth B, Kurz S, Bonomo R. 786. Ceftaroline and Avibactam? Is This a Potential Combination for Mycobacterium abscessus Infection? Open Forum Infectious Diseases 2018, 5: s281-s281. PMCID: PMC6254396, DOI: 10.1093/ofid/ofy210.793.Peer-Reviewed Original ResearchB-lactamB-lactamase inhibitorsMycobacterium abscessus infectionB-lactam antibioticsBenefits of combinationB-lactamaseCeftarolineHydrolyzed penicillinsMycobacterium abscessusAvibactamDiazabicyclooctane inhibitorBlaMabMycobacterial infectionMicrodilution methodClinical modelDiazabicyclooctaneInhibitorsInfectionMICInhibited growthNovel combinationCarbapenemsPotential combinationRelebactamMIC90
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply